Sign In
Buy LGVN
$0.80
-0.0197 (-2.40%)
At Close: Jun 22, 2026
Longeveron Inc. (LGVN) Q3 2025 Earnings Call Transcript
09:36pm, Tuesday, 04'th Nov 2025
Longeveron Inc. ( LGVN ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Than Powell - Interim CEO & Director Nataliya Agafonova - Chief Medical Officer Devin Blass - CTO & Sen
Laromestrocel is a proprietary, scalable, allogeneic cellular therapy being evaluated to improve the clinical outcomes of children with HLHS Full enrollment achieved for pivotal Phase 2b clinical tria
Longeveron® to Participate in the 4th Annual ROTH Healthcare Opportunities Conference
09:15am, Monday, 06'th Oct 2025
MIAMI, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-rel
Longeveron® to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa
09:15am, Monday, 22'nd Sep 2025
Exploring potential partnerships and strategic opportunities for the Company's stem cell therapy program in Alzheimer's disease Alzheimer's disease development program with positive data in successful
Longeveron® Announces Key Leadership Updates
04:05pm, Wednesday, 03'rd Sep 2025
Than Powell, Chief Business Officer and head of business development, appointed Interim CEO Dr. Joshua Hare, co-founder and chief science officer, appointed Executive Chairman of the Board of Director
Longeveron® to Present at the H.C. Wainwright 27th Annual Global Investment Conference
09:15am, Wednesday, 20'th Aug 2025
MIAMI, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric
Longeveron Inc. (LGVN) Q2 2025 Earnings Call Transcript
10:55pm, Wednesday, 13'th Aug 2025
Longeveron Inc. (NASDAQ:LGVN ) Q2 2025 Earnings Conference Call August 13, 2025 4:30 PM ET Company Participants Devin Blass - CTO & Senior VP of Chemistry, Manufacturing, and Controls Joshua Michael H
Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update
04:05pm, Wednesday, 13'th Aug 2025
MIAMI, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric
Longeveron Announces Closing Of Up To $17.5 Million Public Offering
04:15pm, Monday, 11'th Aug 2025
MIAMI, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies
Longeveron Announces Up To $17.5 Million Public Offering
01:28pm, Friday, 08'th Aug 2025
MIAMI, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies
Longeveron® to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025
09:15am, Tuesday, 05'th Aug 2025
MIAMI, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric
Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease
09:15am, Monday, 21'st Jul 2025
Longeveron has licensed issued US Patent 12,168,028 B2 , entitled “Methods for obtaining cardiomyogenic precursor cells” from the University of Miami New patent protects a method to derive GHRH-Re
FDA approves Longeveron's Investigational New Drug (IND) application for stem cell therapy as a potential treatment for pediatric dilated cardiomyopathy.
Longeveron® Appoints Than Powell as Chief Business Officer
09:05am, Thursday, 26'th Jun 2025
Mr. Powell to oversee Longeveron's partnering and international strategy efforts MIAMI, June 26, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotech
Longeveron® completes enrollment of pivotal Phase 2b clinical trial evaluating laromestrocel as a treatment for Hypoplastic Left Heart Syndrome (HLHS).
